Researchers from the University of Missouri School of Medicine have discovered a treatment combination that significantly reduces tumor growth and extends the life span of mice with liver cancer. This discovery provides a ...
Dec 8, 2020
0
172
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from ...
Feb 13, 2021
0
5
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England.
Apr 5, 2019
0
1
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
Aug 21, 2013
0
0
A strategy for giving intermittent, high doses of the anti-cancer drug sunitinib is well-tolerated by patients with advanced cancer and increases concentrations of the drug in tumours, which is associated with improved survival, ...
Oct 24, 2020
0
3
(HealthDay)—For patients with advanced renal cell carcinoma (aRCC), those initiating treatment with nivolumab plus ipilimumab versus sunitinib have longer treatment-free survival (TFS), according to a study published online ...
Dec 3, 2021
0
9
Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial led by a researcher ...
Jan 12, 2015
0
16
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented today at the ESMO 2016 Congress in Copenhagen.
Oct 10, 2016
0
5
Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer, according to a study published online July 5 in the ...
Jul 26, 2023
0
0
(HealthDay)—For patients with previously untreated clear-cell advanced renal-cell carcinoma, nivolumab plus ipilimumab is associated with better overall survival than sunitinib, according to a study published online March ...
Mar 23, 2018
0
4
